{"classes":[{"categories":[{"measurements":[{"comment":"N/A = not estimable as most of the participants were still alive and censored.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"OS is defined as time from first dose of study treatment to death","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"up to 30 days after end of study, approx. 4 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}